Key Highlights

● Repligen fell Friday as life-sciences tools and clinical-stage health care names sold off.

● No company announcement, filing or analyst action on Repligen was reported.

● The 10-year Treasury yield eased to roughly 5.1 after topping 5.3 earlier in October.

● Thermo Fisher, Danaher and Abbott report Oct 21, offering a bioprocessing demand read.

Moving with its group

Repligen (NASDAQ:RGEN), which makes bioprocessing products such as filtration systems, chromatography resins and single-use equipment used to manufacture biologic drugs, fell on Friday, according to market reports. Those reports placed the S&P MidCap 400 member alongside Azenta (NASDAQ:AZTA), Myriad Genetics (NASDAQ:MYGN), Moderna (NASDAQ:MRNA) and PacBio (NASDAQ:PACB) among health care stocks that plummeted, and said Repligen moved with its sector.

No company announcement, filing or analyst action on Repligen was reported for the session.

Rates and long-duration health care

The selling in tools and clinical-stage names was linked to interest rates. Companies whose value depends heavily on growth expected years into the future tend to be sensitive to long-term borrowing costs. The 10-year Treasury yield eased to roughly 5.1 on Friday, but it had climbed above 5.3 earlier in October, its highest level since 2002.

Azenta, which serves the life-sciences sample-management market, fell with life-sciences tools on yields, according to market reports. Novavax (NASDAQ:NVAX) plunged to about $11.20 in what was described as a rate-driven selloff in long-duration and clinical-stage health care, and PacBio plunged to $1.74. QuidelOrtho (NASDAQ:QDEL), Myriad Genetics and Ocular Therapeutix (NASDAQ:OCUL) also fell.

Moderna tumbled as well. Market commentary said investors were trimming positions ahead of Phase 3 data on its intismeran program with Merck (NYSE:MRK), expected later this month, while other reports also pointed to the rate-driven selloff in biotech.

The weakness in smaller health care names contrasted with strength in larger, more defensive parts of the sector. The Health Care Select Sector SPDR Fund hit record highs, per market data, and McKesson (NYSE:MCK) set an intraday record.

The Fed and the market

Federal Reserve Chair Kevin Warsh offered no signal on rates at an IMF gathering in Bangkok. "I don't prejudge meetings," he said. Market reports said his remarks emphasized price stability. The Fed raised rates by a quarter point in September, and futures still price roughly one more quarter-point hike by December.

Inflation data earlier in the week ran hot. September consumer prices rose faster than expected, and producer prices posted their largest monthly increase since March 2022. Import prices also rose more than forecast in data released Friday.

The S&P 500 fell 84.62 points to 7,659.44, the Nasdaq Composite dropped 572.99 points to 26,140.03 and the Dow Jones Industrial Average slipped 175.28 points to 52,002.41. The Russell 2000 lost 45.90 points to about 2,721. No closing level for the S&P MidCap 400 was available. Technology stocks led the declines on worries about how artificial intelligence spending will be financed, while energy, utilities and consumer staples rose. One strategist said, "The good news is that we're starting to see a little bit of improvement in breadth."

Repligen Reads Thermo, Danaher and Abbott

Rates will remain a key driver for the group. The Federal Reserve announces its next decision on Oct 28, and the PCE inflation report and the first estimate of third-quarter GDP are due Oct 29. Moderna's Phase 3 intismeran data, expected later this month, could also influence sentiment toward biotech more broadly.

Life-sciences tools earnings arrive next week. Thermo Fisher Scientific (NYSE:TMO), Danaher (NYSE:DHR) and Abbott Laboratories (NYSE:ABT) report Wednesday, Oct 21, before the open, offering a read on bioprocessing demand and customer spending that is directly relevant to Repligen. Intuitive Surgical (NASDAQ:ISRG) reports Tuesday, Oct 20, after the close.